Highlights • The risks and benefits of ocrelizumab use in older progressive MS patients are not known • Age-related factors may contribute to disability, disease progression, and drug tolerability • Older progressive MS patients on ocrelizumab trend towards decreased disability progression • Ocrelizumab is generally safe and well tolerated in the older progressive MS subpopulation ABSTRACT Background Seminal trials evaluating anti-CD20 therapy in progressive MS primarily found benefit in...
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile